Gujarat Terce Laboratories Ltd
Gujarat Terce Laboratories Ltd (GUJTERC) last reported results for the quarter ended Sep 2021, with sales of ₹10.13 crore and net profit of ₹0.45 crore. The stock last traded at ₹35.6, a market capitalisation of ₹27.7 crore. Over the past 52 weeks the stock has ranged between ₹29 and ₹59.8. Figures are as of 6 Oct 2026 and are not real time.
Gujarat Terce Laboratories Ltd share price and key metrics
- Current price
- ₹35.6
- Market cap
- ₹27.7 cr
- Book value
- ₹13
- ROE
- %
- ROCE
- %
- Dividend yield
- 0.00%
- 52w high / low
- 59.8/29.0
Metrics as of 6 Oct 2026. Not real time.
Track Gujarat Terce Laboratories Ltd
Cruxal reads every Gujarat Terce Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Gujarat Terce Laboratories Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -33%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -1000%
- 10 Years
- 15%
- 5 Years
- 19%
- 3 Years
- 12%
- 1 Year
- -26%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- %
Gujarat Terce Laboratories Ltd quarterly results
In the quarter ended Sep 2021, sales were ₹10.13 cr, up 40.7% from ₹7.2 cr a year earlier. Net profit turned positive at ₹0.45 cr.
| ₹ crore | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Jun 2021 | Sep 2021 |
|---|---|---|---|---|---|---|---|---|
| Sales | 6.94 | 11.15 | 10.11 | 9.34 | 4.98 | 7.2 | 9.94 | 10.13 |
| Expenses | 8.05 | 9.31 | 9.65 | 9.84 | 5.38 | 7.09 | 8.31 | 9.6 |
| Operating profit | -1.11 | 1.84 | 0.46 | -0.5 | -0.4 | 0.11 | 1.63 | 0.53 |
| OPM % | -15.99% | 16.50% | 4.55% | -5.35% | -8.03% | 1.53% | 16.40% | 5.23% |
| Other income | 0 | 0.01 | 0.01 | 0.26 | 0.07 | 0.09 | 0.07 | 0.08 |
| Interest | 0.05 | 0.1 | 0.04 | 0.1 | 0.05 | 0.17 | 0.05 | 0.1 |
| Depreciation | 0.05 | 0.06 | 0.06 | 0.07 | 0.06 | 0.04 | 0.05 | 0.05 |
| Profit before tax | -1.21 | 1.69 | 0.37 | -0.41 | -0.44 | -0.01 | 1.6 | 0.46 |
| Tax % | 0.00% | 0.00% | 0.00% | 39.02% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net profit | -1.22 | 1.69 | 0.37 | -0.57 | -0.44 | -0.02 | 1.6 | 0.45 |
| EPS (₹) | -1.64 | 2.28 | 0.50 | -0.77 | -0.59 | -0.03 | 2.16 | 0.61 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Gujarat Terce Laboratories Ltd annual results
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 |
|---|---|---|---|
| Sales | 31.03 | 37.54 | 25.18 |
| Operating profit | 0.49 | 0.68 | -2.77 |
| OPM % | 1.58% | 1.81% | -11.00% |
| Net profit | 0.43 | 0.28 | -2.52 |
| EPS (₹) | 0.58 | 0.38 | -3.40 |
TTM is the trailing twelve months to the most recent quarter.
Gujarat Terce Laboratories Ltd balance sheet
| ₹ crore | Mar 2019 | Mar 2020 | Sep 2021 |
|---|---|---|---|
| Equity capital | 7.42 | 7.42 | 7.42 |
| Reserves | 3.41 | 3.69 | 2.19 |
| Borrowings | 0.65 | 2.38 | 4.11 |
| Other liabilities | 7.86 | 8.85 | 11.23 |
| Total liabilities | 19.34 | 22.34 | 24.95 |
| Fixed assets | 2.06 | 2.30 | 3.53 |
| CWIP | 0.00 | 0.00 | 0.00 |
| Investments | 0.29 | 0.27 | 0.28 |
| Other assets | 16.99 | 19.77 | 21.14 |
| Total assets | 19.34 | 22.34 | 24.95 |
As reported by the company. Total assets equal total liabilities by construction.
Gujarat Terce Laboratories Ltd operating ratios
| Per year | Mar 2019 | Mar 2020 |
|---|---|---|
| ROCE % | — | 5.85% |
| Debtor days | 53.29 | 68.16 |
| Inventory days | 119.66 | 90.00 |
| Days payable | 88.95 | 83.71 |
| Cash conversion cycle | 83.99 | 74.46 |
| Working capital days | 27.88 | 25.18 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Gujarat Terce Laboratories Ltd shareholding pattern
Promoters held 40.03% at Jun 2026, up from 37.03% at Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 37.03% | 37.03% | 37.03% | 37.03% | 37.03% | 40.03% | 40.03% | 40.03% |
| Public | 62.97% | 62.97% | 62.99% | 62.96% | 62.97% | 59.98% | 59.97% | 59.98% |
| No. of shareholders | 13,538 | 13,710 | 13,764 | 13,804 | 13,812 | 13,805 | 13,750 | 13,755 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Gujarat Terce Laboratories Ltd corporate filings
- Detailed disclosure is attached.Company Updatelow impact
- Detailed disclosure is attached.Insider Trading / SASTlow impact
- Gujarat Terce Laboratories Limited Announces Successful Conclusion of 41st Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: Gujarat Terce Laboratories Limited has successfully concluded its 41st Annual General…
Read the full analysis - Gujarat Terce Laboratories Limited concludes 41st Annual General Meeting and approves key management re-appointmentsAGM/EGMlow impact
Cruxal's analysis: Gujarat Terce Laboratories Limited has successfully concluded its 41st Annual General…
Read the full analysis - Gujarat Terce Laboratories Limited announces re-appointment of Mr. Aalap Prajapati as Managing Director & CEOCompany Updatelow impact
Cruxal's analysis: Gujarat Terce Laboratories Limited has formally announced the re-appointment of Mr. Aalap…
Read the full analysis - Gujarat Terce Laboratories Limited clarifies MD & CEO re-appointment tenure following shareholder approvalCompany Updatelow impact
Cruxal's analysis: Gujarat Terce Laboratories Limited has issued a corrigendum to rectify an inadvertent…
Read the full analysis - Gujarat Terce Laboratories Ltd publishes mandatory newspaper notice for regulatory complianceCompany Updatelow impact
Cruxal's analysis: Gujarat Terce Laboratories Ltd has released a newspaper publication as part of its…
Read the full analysis - Gujarat Terce Laboratories reports Q1 FY2027 net loss of 17.81 lakh amid revenue contractionResulthigh impact
Cruxal's analysis: Gujarat Terce Laboratories Limited reported a weak performance for the quarter ended 30…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.